Literature DB >> 11170284

Characterization of complex chromosomal abnormalities in uveal melanoma by fluorescence in situ hybridization, spectral karyotyping, and comparative genomic hybridization.

N C Naus1, E van Drunen, A de Klein, G P Luyten, D A Paridaens, J C Alers, B R Ksander, H B Beverloo, R M Slater.   

Abstract

Several nonrandom recurrent chromosomal changes are observed in uveal melanoma. Some of these abnormalities, e.g., loss of chromosome 3, gain of the q arm of chromosome 8, and chromosome 6 abnormalities, are of prognostic value. Cytogenetic analysis and/or fluorescence in situ hybridization (FISH) are used to detect these changes. In some cases, however, detailed cytogenetic analysis is not possible due to the presence of complex abnormalities. To define more accurately these cytogenetic changes, we have applied comparative genomic hybridization (CGH) and/or spectral karyotyping (SKY) to two uveal melanoma cell lines and five primary uveal melanomas, with partially defined and/or complex abnormalities. SKY provided additional information on 34/39 partially defined aberrant chromosomes and revealed a new abnormality, a der(17)t(7;17)(?;q?), that had not been recognized by conventional cytogenetics. Additionally, using SKY, abnormalities involving chromosome 6 or 8 were found to be twice as common as observed with cytogenetic analysis. CGH was especially useful in assigning the abnormalities identified by SKY to specific chromosomal regions and, in addition, resulted in the detection of a small deletion of chromosome region 3q13 approximately 21. We conclude that SKY and CGH, as methods complementary to cytogenetic and FISH analysis, provide more complete information on the chromosomal abnormalities occurring in uveal melanoma. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11170284

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  11 in total

Review 1.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 2.  Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).

Authors:  Martine J Jager; J Antonio Bermudez Magner; Bruce R Ksander; Sander R Dubovy
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

3.  A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile.

Authors:  J William Harbour
Journal:  Methods Mol Biol       Date:  2014

4.  Clinical and histopathological features and immunoreactivity of human choroidal and ciliary melanomas as prognostic factors for metastasis and death.

Authors:  Camila C Simões; Mindy K Call; Zélia M Corrêa; Abbot G Spaulding; James J Augsburger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-17       Impact factor: 3.117

Review 5.  Choroidal biopsies; a review and optimised approach.

Authors:  R N Hussain; B Damato; H Heimann
Journal:  Eye (Lond)       Date:  2022-08-08       Impact factor: 4.456

Review 6.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

7.  Ocular melanoma.

Authors:  Bertil E Damato; Sarah E Coupland
Journal:  Saudi J Ophthalmol       Date:  2012-04

Review 8.  Molecular prognostic testing and individualized patient care in uveal melanoma.

Authors:  J William Harbour
Journal:  Am J Ophthalmol       Date:  2009-10-02       Impact factor: 5.258

Review 9.  Genetic determinants of uveal melanoma.

Authors:  Jasbir Kaur; Manzoor Ahmad Malik; Rishabh Gulati; Shorya Vardhan Azad; Sandeep Goswami
Journal:  Tumour Biol       Date:  2014-10-09

10.  Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3.

Authors:  S Hughes; B E Damato; I Giddings; P S Hiscott; J Humphreys; R S Houlston
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.